SEC Company Response from Brickell Biotech, Inc. (FRTX) (CIK 0000819050) — Oct 20, 2020
Brickell Biotech, Inc. (FRTX) (CIK 0000819050)
Date: Oct. 20, 2020 · CIK: 0000819050 · Accession: 0000819050-20-000212
AI Filing Summary & Sentiment
File numbers found in text: 333-249441
Letter
Document
Oppenheimer & Co. Inc.
85 Broad Street
New York, NY 10004
October 20, 2020
U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Re: Brickell Biotech, Inc. (the “Company”)
Registration Statement on Form S-1 (File No. 333-249441)
Ladies and Gentlemen:
In connection with the above-captioned registration statement, and pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Oppenheimer & Co. Inc., as the representative of the underwriters, hereby joins in the request of the Company that the effective date of such registration statement be accelerated to 4:15 p.m. (New York time) on October 22, 2020, or as soon thereafter as practicable.
In making this request the undersigned acknowledges that the underwriters are aware of their obligations under the Act as they relate to the public offering of securities pursuant to the registration statement.
[Signature Page Follows]
Very truly yours,
OPPENHEIMER & CO. INC.
Show Raw Text
CORRESP 1 filename1.htm Document Oppenheimer & Co. Inc. 85 Broad Street New York, NY 10004 October 20, 2020 U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Brickell Biotech, Inc. (the “Company”) Registration Statement on Form S-1 (File No. 333-249441) Ladies and Gentlemen: In connection with the above-captioned registration statement, and pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), Oppenheimer & Co. Inc., as the representative of the underwriters, hereby joins in the request of the Company that the effective date of such registration statement be accelerated to 4:15 p.m. (New York time) on October 22, 2020, or as soon thereafter as practicable. In making this request the undersigned acknowledges that the underwriters are aware of their obligations under the Act as they relate to the public offering of securities pursuant to the registration statement. [Signature Page Follows] Very truly yours, OPPENHEIMER & CO. INC. As the Representative of the Underwriters By: /s/ Michael A. Margolis, R.Ph. Name: Michael A. Margolis, R.Ph. Title: Managing Director, Co-Head of Healthcare Investment Banking -2-